Analysis of secretome of breast cancer cell line with an optimized semi-shotgun method

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Analysis of secretome of breast cancer cell line with an optimized semi-shotgun method

TANG Xiaorong，

YAO Ling，

CHEN Keying，

HU Xiaofang，

XU Lisa X.，

FAN Chunhai

Nuclear Science and Techniques

Vol.20, No.5

pp.286-291

Published in print 20 Oct 2009

DOI：10.13538/j.1001-8042/nst.20.286-291

63200

Secretome, the totality of secreted proteins, is viewed as a promising pool of candidate cancer biomarkers. Simple and reliable methods for identifying secreted proteins are highly desired. We used an optimized semi-shotgun liquid chromatography followed by tandem mass spectrometry (LC-MS/MS) method to analyze the secretome of breast cancer cell line MDA-MB-231. A total of 464 proteins were identified. About 63% of the proteins were classified as secreted proteins, including many promising breast cancer biomarkers, which were thought to be correlated with tumorigenesis, tumor development and metastasis. These results suggest that the optimized method may be a powerful strategy for cell line secretome profiling, and can be used to find potential cancer biomarkers with great clinical significance.

SecretomeSemi-shotgunBreast cancer

References

[1]

Kulasingam V, Diamandis E P. Int J Cancer, 2008, 123(9): 2007-2012.

[2]

Balk S P, Ko Y J, Bubley G J. J Clin Oncol, 2003, 21(2): 383-391.

[3]

Hathout Y, Expert Rev Proteomics, 2007, 4(2): 239-248.

[4]

Huang Lingjin, Chen Shengxi, Hunag Yan, et al. Lung Cancer, 2006, 54(1): 87-94.

[5]

Volmer M W, Stuhler K, Zapatka M, et al. Proteomics, 2005, 5(10): 2587-2601.

[6]

Lin C Y, Tsui K H, Yu C C, et al. Proteomics, 2006, 6(15): 4381-4389.

[7]

Weng L P, Wu C C, Hsu B L, et al. J Proteome Res, 2008, 7(9): 3765-3775.

[8]

Kreunin P, Urquidi V, Lubman D M, et al. Proteomics, 2004, 4(9): 2754-2765.

[9]

Sardana G, Marshall J, Diamandis E P. Clin Chem, 2007, 53(3): 429-437.

[10]

Kulasingam V, Diamandis E P. Mol Cell Proteomics, 2007, 6(11): 1997-2011.

[11]

Mbeunkui F, Metge B J, Shevde L A, et al. J Proteome Res, 2007, 6(8): 2993-3002.

[12]

Valko M, Rhodes C J, Moncol J, et al. Chem-Biol Interact, 2006, 160(1): 1-40.

[13]

Kazerounian S, Yee K O, Lawler J, Cell Mol Life Sci, 2008, 65(5): 700-712.

[14]

Grassadonia A, Tinari N, Iurisci I, et al. Glycoconjugate J, 2004, 19(7-9) 551-556.

[15]

Binder B R, Mihaly J. Immunol Lett, 2008, 118(2): 116-124.

[16]

Keppler D. Cancer Lett, 2006, 235(2): 159-176.

[17]

Annecke K, Schmitt M, Euler U, et al. Adv Clin Chem, 2008, 45: 31-45.

[18]

Molina R, Barak V, van Dalen A, et al. Tumour Biol, 2005, 26(6): 281-293.

[19]

Iacobelli S, Arno' E, D'Orazio A, et al. Cancer Res A, 1986, 46: 3005-3010.

[20]

Iacobelli S, Arno' E, Sismondi P, et al. Breast Cancer Res Treat, 1988, 11(1): 19-30.

[21]

Fusco O, Querzoli P, Nenci I, et al. Int J Cancer, 1998, 79(1): 23-26.

[22]

Natoli C, Garufi C, Tinari N, et al. Br J Cancer, 1993, 67(3): 465-467.

[23]

Park Y P, Choi S C, Kim J H, et al. Int J Cancer, 2007, 120(4): 813-820.

[24]

Lacovazzi P A, Trisolini A, Barletta D, et al. Clin Chem Lab Med, 2001, 39(10): 961-965.

[25]

Brguljan P M, Cimerman N. Turk J Biochem, 2007, 32 (3): 95-103.

[26]

Decock J, Obermajer N, Vozelj S, et al. Int J Biol Markers, 2008, 23(3): 161-168.

[27]

Zinkin N T, Grall F, Bhaskar K, et al. Clin Cancer Res, 2008, 14(2): 470-477.